News coverage about Cerulean Pharma (NASDAQ:CERU) has been trending positive recently, according to AlphaOne. AlphaOne, a unit of Accern, identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cerulean Pharma earned a media sentiment score of 0.26 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biotechnology company an impact score of 100 out of 100, meaning that recent media coverage is extremely likely to have an effect on the company’s share price in the immediate future.
Cerulean Pharma (NASDAQ:CERU) traded up 7.2286% on Friday, reaching $0.4198. 428,075 shares of the company traded hands. The stock’s market capitalization is $12.18 million. Cerulean Pharma has a 52-week low of $0.33 and a 52-week high of $3.58. The firm has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.91.
WARNING: This article was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/05/20/cerulean-pharma-ceru-earning-positive-media-coverage-study-finds.html.
About Cerulean Pharma
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
Receive News & Ratings for Cerulean Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.